It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...

Usually, official talks are mere formalities – meetings to ink things that have already been agreed upon. The one scheduled between the US ...

With Israel refusing to play ball and Iran maintaining its vice-like hold on the Strait of Hormuz, the ceasefire declared by US President T...

The market is again abuzz with the possibility of peace in the Gulf. This has, however, happened in the past. There is, thus, no point in g...

The rising stock price of a company does not mean that the business is strong. And a falling stock price does not mean that the business is...

While Democrats are better known to push for lower drug prices in the US, in recent times even Republicans are talking about keeping the co...

Here’s a lesson from history: For a long-term investor, buying in a correcting market is mostly an opportunity. The operative part, of cour...

When it comes to large-caps, we think of Reliance, TCS, L&T or Infosys. The fact, however, is that these are not large-caps – they are mega...

At a time when the Nifty and Sensex are trading with cuts in excess of 1%, talking of buying stocks may not appear quite right. But correct...

There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did ...

There are many textbook definitions of the word “ moat”. But what it means in simple terms is that there has to be something in a business ...

There cannot be any doubt about volatility on the street, both as reflected by advance decline ratio or the kind of movement we see in nift...

While all pharma companies get classified into one sector they are very different at molecular level. Each company has its own operating ma...

In the proposed offer for sale, existing investors ChrysCapital will sell about 1% stake, Capital International will sell another 6% while ...

Pfizer and Abbott and domestic companies including Alkem, Ipca and MacLeods, and is likely to be contested by companies, sources say.

Next time your child refuses to take the diarohhea syrup, don’t blame the poor kid. The change in the chemical composition of popular paedi...

Delhi-based Mankind Pharma is holding parleys with some of the leading private equity funds for a private placement deal.